Aller au contenu principal

 Articles scientifiques

Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets.

Auteurs : Zambelli A, Sgarra R, De Sanctis R, Agostinetto E, Santoro A, Manfioletti G
Année : 2022
Journal : Expert Opin Ther Targets
Volume : 26
Pages : 557-573

Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial.

Auteurs : Dal Lago L, Uwimana AL, Coens C, Vuylsteke P, Curigliano G, Brouwers B, Jagiello-Gruszfeld A, Altintas S, Tryfonidis K, Poncet C, Bottomley A, Sousa B, Brain E, Wildiers H
Année : 2022
Journal : J Geriatr Oncol
Volume : 13
Pages : 582-593

Delivering precision oncology to patients with cancer.

Auteurs : Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, Geissler J, Husereau D, Martinez-Lopez I, Normanno N, Reis-Filho JS, Stefani S, Thomas DM, Westphalen CB, Voest E
Année : 2022
Journal : Nat Med
Volume : 28
Pages : 658-665

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.

Auteurs : Chang CA, Jen J, Jiang S, Sayad A, Mer AS, Brown KR, Nixon AML, Dhabaria A, Tang KH, Venet D, Sotiriou C, Deng J, Wong KK, Adams S, Meyn P, Heguy A, Skok JA, Tsirigos A, Ueberheide B, Moffat J, Singh A, Haibe-Kains B, Khodadadi-Jamayran A, Neel BG
Année : 2022
Journal : Cancer Discov
Volume : 12
Pages : 1022-1045

Efficacy of pharmacologic treatment for treating gastrointestinal angiodysplasias-related bleeding: a systematic review and meta-analysis.

Auteurs : Gkolfakis P, Fostier R, Tziatzios G, Lazaridis N, Fernandez Y Viesca M, Facciorusso A, Despott E, Triantafyllou K, Devière J, Arvanitakis M
Année : 2022
Journal : Eur J Gastroenterol Hepatol
Volume : 34
Pages : 1021-1030

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma.

Auteurs : Najem A, Soumoy L, Sabbah M, Krayem M, Awada A, Journe F, Ghanem GE
Année : 2022
Journal : Cells
Volume : 11

Results of a single-arm pilot study of (32)P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy.

Auteurs : Ross PJ, Wasan HS, Croagh D, Nikfarjam M, Nguyen N, Aghmesheh M, Nagrial AM, Bartholomeusz D, Hendlisz A, Ajithkumar T, Iwuji C, Wilson NE, Turner DM, James DC, Young E, Harris MT
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100356

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer.

Auteurs : Agostinetto E, Jacobs F, Debien V, De Caluwé A, Pop CF, Catteau X, Aftimos P, de Azambuja E, Buisseret L
Année : 2022
Journal : Cancers (Basel)
Volume : 14

Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.

Auteurs : Longo-Muñoz F, Castellano D, Alexandre J, Chawla SP, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Moreno V, Sanz-García E, Awada A, Santaballa A, Subbiah V
Année : 2022
Journal : Eur J Cancer
Volume : 172
Pages : 340-348

Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.

Auteurs : Salgado R, Fineberg S, De Caluwe A, de Azambuja E
Année : 2022
Journal : Eur J Cancer
Volume : 168
Pages : 138-140

Incidental finding of solitary fibrous tumor of male breast: case report and review of literature.

Auteurs : El-Helou E, Zaiter M, Hoang H, Lelie B, Larsimont D, Awada A, Grosu F, Veys I, Pop CF
Année : 2022
Journal : Rom J Morphol Embryol
Volume : 63
Pages : 653-657

Corrigendum to 'p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib'[Eur J of Cancer 55 (2016) 98-110].

Auteurs : Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, Van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G
Année : 2022
Journal : Eur J Cancer
Volume : 175
Pages : 336-338

Frailty in older adults with cancer (Fabio Gomez, editor) - Part III : Breast cancer in older adults with frailty

Auteurs : Dal Lago L, De Caluwe A, Borghgraef C, Dumont L, Pepersack T
Année : 2022
Journal : Book
Volume : part III
Pages : 303 - 318

Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations.

Auteurs : Conforti F, Pala L, Bagnardi V, De Pas T, Colleoni M, Buyse M, Hortobagyi G, Gianni L, Winer E, Loibl S, Cortes J, Piccart-Gebhart M, Wolff AC, Viale G, Gelber Rd
Année : 2022
Journal : JAMA Oncol
Volume : 8
Pages : 1668-1675

What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.

Auteurs : Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV
Année : 2022
Journal : Cancer Med
Volume : 11
Pages : 332-339

PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment.

Auteurs : Thouvenin J, Van Marcke C, Decoster L, Raicevic G, Punie K, Vandenbulcke M, Salgado R, Van Valckenborgh E, Maes B, Joris S, Steichel DV, Vranken K, Jacobs S, Dedeurwaerdere F, Martens G, Devos H, Duhoux FP, Rasschaert M, Pauwels P, Geboes K, Collignon J, Tejpar S, Canon JL, Peeters M, Rutten A, Van de Mooter T, Vermeij J, Schrijvers D, Demey W, Lybaert W, Van Huysse J, Mebis J, Awada A, Claes KBM, Hebrant A, Van der Meulen J, Delafontaine B, Bempt IV, Maetens J, de Hemptinne M, Rottey S, Aftimos P, De Grève J
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100524

The Managing Advanced Cancer Pain Together (MACPT) conversation tool: an evaluation of use in clinical practice.

Auteurs : Quinn B, Laurent S, Dargan S, Lapuente M, Lüftner D, Drudge-Coates L, Palma MD, Dal Lago L, Flynn J, Panter C, Seesaghur A
Année : 2022
Journal : Pain Manag
Volume : 12
Pages : 435-446

Systemic therapy for early-stage breast cancer: learning from the past to build the future.

Auteurs : Agostinetto E, Gligorov J, Piccart-Gebhart M
Année : 2022
Journal : Nat Rev Clin Oncol
Volume : 19
Pages : 763-774

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.

Auteurs : Robbrecht D, Jungels C, Sorensen MM, Spanggaard I, Eskens F, Fretland SØ, Guren TK, Aftimos P, Liberg D, Svedman C, Thorsson L, Steeghs N, Awada A
Année : 2022
Journal : Br J Cancer
Volume : 126
Pages : 1010-1017

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.

Auteurs : Nader-Marta G, Martins-Branco D, Agostinetto E, Bruzzone M, Ceppi M, Danielli L, Lambertini M, Kotecki N, Awada A, de Azambuja E
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100501